JP2006089491A - 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク - Google Patents
非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク Download PDFInfo
- Publication number
- JP2006089491A JP2006089491A JP2005292358A JP2005292358A JP2006089491A JP 2006089491 A JP2006089491 A JP 2006089491A JP 2005292358 A JP2005292358 A JP 2005292358A JP 2005292358 A JP2005292358 A JP 2005292358A JP 2006089491 A JP2006089491 A JP 2006089491A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cell
- complex
- specificity
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
【解決手段】毒素とサイトカインの複合体、および悪性細胞に特有の細胞マーカーに対する第1特異性とIL−15αの領域に対する特異性を有する二重特異性抗体を含む融合タンパクは、各々、場合に応じて放射核種をさらに含み、白血病およびリンパ腫を治療するための有用な治療用試薬となる。
【選択図】なし
Description
5種のBリンパ腫細胞系ならびに非B細胞系(IL−2Rβ/γcを発現することが判明しているT細胞系、MLA 144、およびAML由来の細胞系、MB−02)の、IL−15およびIL−2結合を分析した。125I標識したrIL−15を使用した。IL−15Rαの全結合への分布の推定を可能にするために、IL−2とIL−15の両者を用いて寒冷リガンド阻害を実施した。
3種の異なるmAb、すなわち、クラスII非変異鎖LL1、抗CD22抗体LL2、および抗トランスフェリン受容体抗体を、2種のRNaseスーパーファミリー毒素、すなわちオンコナーゼおよびEDNに結合させた。結果として生じる複合体を、3種のBリンパ腫細胞系Daudi、Raji、CA−46、乳癌細胞系MDA−MB−231、およびヒトT細胞系HuT102を含む細胞系団で試験した。結果から、LL2−オンコナーゼは、試験した全ての複合体の中で最低のIC50値を有することがわかった。オンコナーゼを主成分とする免疫毒素の、Bリンパ腫細胞系Daudiに対する毒性は、オンコナーゼとLL2複合体でさらに証明された。LL2はCD22に対する抗体であり、効率よくインターナライズする抗原である。全IgG複合体とFab(複合体の両者を調製し、ナノモル濃度未満の範囲でこの細胞系を阻害することを確認した。過剰の冷抗体で阻害作用がほぼ消失するため、その効果は、複合体のCD22反応性次第であることが証明された。
ハイブリドーマ1F5、IgG2a kは、RockvilleのAmerican Type Culture Collectionから入手できる。このハイブリドーマーを使用し、組織培養および/または腹水でのハイブリドーマの成長、およびその後のプロテインA−アガロースによる精製によってmAbを作る。これを、2mL L−グルタミンおよび各50μg/mlのペニシリンおよびストレプトマイシンおよび10%FCSを加えたRPMI1640中で培養する。
sIL−15Rα−VH−GGGGSQPK(GGGGS)2−VL
形質転換コロニーを採取し、LBブロス中でOD600=約0.5まで発育させる。次いでこれを、0.4mM IPTGを用いて37℃で3〜6時間、発現タンパクに導入する。小規模培養由来の細菌細胞をペレット化させ、SDS−PAGE試料緩衝液で溶解し、遠心分離で崩壊物(debris)を除去し、部分標本を10%SDS−PAGEゲルに負荷する。ゲルの一部を切り取り、クマシーブルー(Coomassie Blue)で染色し、その残りをImmobilon-P膜にトランスブロットする。この膜を、ヘキサヒスチジンタグを認識するニッケル−アルカリホスファターゼ複合体(Qiagen, Chatsworth, CA)か、免疫グロブリンを検出するためのヤギ抗マウスアルカリホスファターゼ(Kirkegaard and Perry, Gaithersburg, MD)のいずれかで染色する。ブロットをECL基質CSPDで展開し、写真フィルムに曝露する。
比放射能が20μCi/μgを超えないように、ヨードジェン法によって融合タンパクを125Iで放射標識することにより、融合タンパクの抗原結合活性を分析する。CD20陽性またはCD20陰性であることが判明しているヒト細胞系の一団を、冷1F5、冷融合タンパクおよび冷IL−15の存在下または非存在下で、標準結合分析法で試験する。結合は、抗CD20部分を介して起こる。氷上で1時間後、80/20のジブチルフタレート/オリーブ油のクッションを介してスピンさせ、チューブの先端を細胞を切り取ってガンマーカウンターでカウントする。
融合タンパクおよび親1F5は、同時に125Iで標識する。CD20+細胞系RLを使用する。結合は、両標識とも等しい細胞部分標本を用いて、5nMで、氷上で実施する。インターナリゼーションに対する影響を評価するために、冷IL−15または冷IL−2を同じ試験管に加える。細胞をペレット化させ、洗浄することによって、未結合標識を除去する。t0値を求め、残りの部分標本を37℃に置き、様々な時間間隔で取り出す。異化され、放出された125Iは、10%TCAで沈澱させることによって、解離した、もとのままのタンパク標識と区別される。冷IL−15を標識融合タンパクに加えてコントロールには加えないときにインターナリゼーションの増強が起これば、in vivo状態に近づけるために、標識IL−15と未標識融合タンパクを使用した逆の実験を実施する。
一般に、IL−15とオンコナーゼから成る融合タンパクは、Rybak(1995)に略述されているmAbオンコナーゼ融合タンパクを産生するための手順に従って操作する。簡単に記述すると、成熟IL−15タンパクに相応する、配列が確認されたフラグメントを、5(に存在するIL−15配列でオンコナーゼの配列に結合するが、別の方向を評価することもできる。オンコナーゼ遺伝子を2種以上のカエルからクローン化する。C末端ヘキサヒスチジンタグを使用して、融合配列を表す真正フラグメントをpET21dベクターに再度サブクローニングする。IL−15−オンコナーゼ融合タンパク全部をコード化している全配列を、上述のXL1Blue菌株のpETベクターで確認する。適当なクローンを生育させて、AD494(DE3)E. coli発現菌株のトランスフォーメーション用のプラスミドを作る。
オンコナーゼを主成分とする免疫毒素の細胞活性をBリンパ腫細胞系で評価するために、LL2−オンコナーゼ複合体を調製し、その作用をDaudi、Bリンパ腫細胞系で試験した。全IgG複合体とFab(複合体の両者を調製し、ナノモル濃度未満の範囲でこの細胞系を阻害することを確認した。さらに、過剰の冷抗体によって阻害作用がほぼ消失したことから、この作用は、複合体のCD22反応依存性であることもわかった。
例3および4に従って調製したリン酸緩衝食塩水(PBS)中の123I標識融合タンパク、sIL−15Rα−1F5scFの目標量を含む無菌の無発熱物質溶液を、B−CLL患者に静脈内注入する。融合タンパクが悪性B細胞に結合し、ガンマカメラ画像でモニタリングされるように、患者の循環から実質的に取り除かれた後で、例7に従って調製したIL−15/オンコナーゼ免疫毒素の治療用量を含む無菌の無発熱物質溶液を患者に注入する。その後の標識抗CD20を用いた放射免疫検出から、リンパ腫の著明な減少がわかる。
Claims (19)
- 非免疫原性毒素または治療用放射性核種と細胞特異的サイトカインとの複合体。
- 前記毒素がRNaseであることを特徴とする、請求項1に記載の複合体。
- 前記サイトカインがIL−15であることを特徴とする、請求項1に記載の複合体。
- 前記毒素がオンコナーゼであることを特徴とする、請求項3に記載の複合体。
- 診断用放射性核種をさらに含む、請求項4に記載の複合体。
- 請求項1に記載の複合体と、医薬的に許容できるキャリヤーを含む組成物。
- 前記サイトカインに結合した診断用放射核種をさらに含む、請求項6に記載の組成物。
- 悪性細胞に特有の細胞マーカーに対する第1特異性とIL−15αの領域に対する第2特異性を有する二重特異性抗体を含む融合タンパク。
- 前記二重特異性抗体がscFvであることを特徴とする、請求項8に記載の融合タンパク。
- 前記scFvが個々scFv分子2個の融合物であることを特徴とする、請求項9に記載の融合タンパク。
- 前記細胞マーカーがB細胞限定抗原であることを特徴とする、請求項8に記載の融合タンパク。
- 前記細胞マーカーがCD20であることを特徴とする、請求項11に記載の融合タンパク。
- 前記IL−15αの領域がIL−15α細胞外ドメインであることを特徴とする、請求項8に記載の融合タンパク。
- 請求項8に記載の融合タンパクと医薬的に許容できるキャリヤーを含む組成物。
- オンコナーゼとIL−15の複合体と、悪性細胞に特有の細胞マーカーに対する第1特異性とIL−15αの領域に対する第2特異性を有する二重特異性抗体を含む融合タンパクとを含むキット。
- 悪性細胞に特有の細胞マーカーに対する第1特異性とIL−15αの領域に対する特異性を有する二重特異性抗体を含む融合タンパクを、悪性腫瘍被験者に最初に投与するステップと、次いでオンコナーゼとIL−15の複合体の治療有効量を前記被験者に投与するステップとを含む悪性腫瘍を治療する方法。
- 化学療法および放射線療法の少なくとも1つを、腫瘍細胞がDNA修復機構を活性化するのを防止するのに十分な量で投与するステップをさらに含む、請求項16に記載の方法。
- 前記細胞マーカーがB細胞限定抗原であり、前記被験者がB細胞悪性腫瘍を有することを特徴とする、請求項16に記載の方法。
- 前記細胞マーカーがCD20であり、前記被験者がリンパ性白血病、非ホジキン型リンパ種、毛状細胞性白血病または急性骨髄製白血病を有することを特徴とする、請求項18に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2843096P | 1996-10-17 | 1996-10-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51840298A Division JP2001503253A (ja) | 1996-10-17 | 1997-10-14 | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006089491A true JP2006089491A (ja) | 2006-04-06 |
JP4056543B2 JP4056543B2 (ja) | 2008-03-05 |
Family
ID=21843399
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51840298A Pending JP2001503253A (ja) | 1996-10-17 | 1997-10-14 | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク |
JP2005292358A Expired - Fee Related JP4056543B2 (ja) | 1996-10-17 | 2005-10-05 | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51840298A Pending JP2001503253A (ja) | 1996-10-17 | 1997-10-14 | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク |
Country Status (11)
Country | Link |
---|---|
US (4) | US6083477A (ja) |
EP (1) | EP0932417B1 (ja) |
JP (2) | JP2001503253A (ja) |
AT (1) | ATE233573T1 (ja) |
AU (1) | AU729515B2 (ja) |
CA (1) | CA2269060C (ja) |
DE (1) | DE69719529T2 (ja) |
DK (1) | DK0932417T3 (ja) |
ES (1) | ES2191827T3 (ja) |
PT (1) | PT932417E (ja) |
WO (1) | WO1998016254A1 (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL114909A (en) * | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6653104B2 (en) * | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
AU729515B2 (en) * | 1996-10-17 | 2001-02-01 | Immunomedics Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
CA2288232A1 (en) * | 1997-05-02 | 1998-11-12 | The Government Of The United States, Represented By The Secretary, Depar Tment Of Health And Human Services | Immunotoxins directed against malignant cells |
CA2302360C (en) | 1997-09-03 | 2005-11-15 | Immunomedics, Inc. | Fluorination of proteins and peptides for f-18 positron emission tomography |
US6703488B1 (en) | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
AU2226799A (en) * | 1998-01-15 | 1999-08-02 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
US6869604B1 (en) * | 1998-03-27 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant anti-tumor RNAse |
EP1176981B1 (en) | 1999-05-07 | 2005-11-30 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7045283B2 (en) * | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
BR0212136A (pt) * | 2001-08-23 | 2004-12-07 | Genmab As | Anticorpo monoclonal humano isolado, métodos para inibir a produção de tnfa em células t ou monócitos e a proliferação de célula t, hibridoma, transfectoma, animal não humano transgênico, método para produzir um anticorpo monoclonal humano, composição farmacêutica, métodos para tratar ou prevenir um distúrbio mediado pela il-15 humana, a psorìase e a artrite reumatóide, método para diagnosticar uma doença, ácido nucleico, e, vetor de expressão |
US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
CA2513287A1 (en) * | 2002-01-14 | 2003-07-17 | William Herman | Multispecific binding molecules |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
WO2005069994A2 (en) * | 2004-01-22 | 2005-08-04 | Immunomedics, Inc. | Folate conjugates and complexes |
US8470315B2 (en) * | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
AU2005335217A1 (en) * | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of B cell proliferation by IL-15 |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
EP1919515A4 (en) | 2005-08-31 | 2011-06-22 | Immunomedics Inc | F-18 PEPTIDES FOR PRECIBLE POSITRON EMISSION TOMOGRAPHY IMAGING |
JP2009531324A (ja) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体 |
JP2009541333A (ja) * | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
EP2049151A4 (en) | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
EA034877B1 (ru) | 2006-09-26 | 2020-04-01 | Генмаб А/С | Способ комбинированной терапии опухолей, экспрессирующих cd38, и терапевтическая комбинация для применения в указанном способе |
JPWO2008133141A1 (ja) * | 2007-04-24 | 2010-07-22 | 東洋紡績株式会社 | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
EP2197491A4 (en) | 2007-09-04 | 2011-01-12 | Univ California | HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER |
US8697062B2 (en) * | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
CA3170329A1 (en) | 2008-01-15 | 2009-07-23 | Siddhartha Jaiswal | Methods for manilpulating phagocytosis mediated by cd47 |
JP2011518313A (ja) | 2008-01-15 | 2011-06-23 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 急性骨髄性白血病幹細胞のマーカー |
US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
JP2012504423A (ja) | 2008-10-01 | 2012-02-23 | クインテッセンス バイオサイエンシズ,インコーポレーテッド | 治療用リボヌクレアーゼ |
EP3903829B1 (en) | 2009-02-13 | 2023-05-03 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
JP5906090B2 (ja) | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated | 癌の診断のための方法およびキットならびに治療価の推定 |
GB0905438D0 (en) * | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
WO2010118890A1 (en) | 2009-04-16 | 2010-10-21 | Charite - Universitätsmedizin Berlin | B-lymphocyte targeting agents for use in a method for the treatment of a disease |
KR20240007725A (ko) | 2009-11-02 | 2024-01-16 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료학적 뉴클레아제 조성물 및 방법 |
JP6251477B2 (ja) | 2009-12-02 | 2017-12-20 | イマジナブ・インコーポレーテッド | ヒト前立腺特異的膜抗原(psma)をターゲッティングするj591ミニボディおよびcysダイアボディならびにこれらを使用するための方法 |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
EA201391585A1 (ru) | 2011-04-29 | 2014-04-30 | Юниверсити Оф Вашингтон | Терапевтические нуклеазные композиции и способы |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
SG11201405468QA (en) | 2012-03-14 | 2014-10-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
EP2861259A1 (en) | 2012-06-14 | 2015-04-22 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
CN118001422A (zh) | 2012-12-13 | 2024-05-10 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
ES2892525T3 (es) | 2014-10-07 | 2022-02-04 | Immunomedics Inc | Uso neoadyuvante de conjugados anticuerpo-fármaco |
BR112017011749A2 (pt) | 2014-12-04 | 2018-05-15 | Janssen Biotech Inc | anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda |
AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
ES2953441T3 (es) | 2015-06-25 | 2023-11-13 | Immunomedics Inc | Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
SG10202112460VA (en) | 2015-07-06 | 2021-12-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
JP6966424B2 (ja) | 2015-09-09 | 2021-11-17 | フレッド ハッチンソン キャンサー リサーチ センター | 軟骨ホーミングペプチド |
RS63210B1 (sr) | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
EP3571215A4 (en) | 2017-01-18 | 2020-12-30 | Fred Hutchinson Cancer Research Center | PEPTIDE COMPOSITIONS AND METHOD OF USE THEREOF TO INTERRUPT TEAD INTERACTIONS |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
CN110475565A (zh) | 2017-03-16 | 2019-11-19 | 光明之火生物科学公司 | 软骨归巢肽缀合物及其使用方法 |
WO2018226861A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
US11331393B2 (en) | 2017-06-15 | 2022-05-17 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837003A (en) * | 1984-09-13 | 1989-06-06 | Mallinckrodt, Inc. | Radiolabeled antibody fragments |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
JPH05508634A (ja) * | 1990-07-05 | 1993-12-02 | アクゾ・エヌ・ヴエー | レセプター特異的トキシン結合体 |
US5346686A (en) * | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
US5591630A (en) * | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
AU729515B2 (en) * | 1996-10-17 | 2001-02-01 | Immunomedics Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
TW581136U (en) * | 2002-10-08 | 2004-03-21 | Nien Made Entpr Co Ltd | Structure of wooden blind window |
-
1997
- 1997-10-14 AU AU48079/97A patent/AU729515B2/en not_active Ceased
- 1997-10-14 PT PT97910793T patent/PT932417E/pt unknown
- 1997-10-14 CA CA002269060A patent/CA2269060C/en not_active Expired - Fee Related
- 1997-10-14 DE DE69719529T patent/DE69719529T2/de not_active Expired - Lifetime
- 1997-10-14 JP JP51840298A patent/JP2001503253A/ja active Pending
- 1997-10-14 ES ES97910793T patent/ES2191827T3/es not_active Expired - Lifetime
- 1997-10-14 WO PCT/US1997/017924 patent/WO1998016254A1/en active IP Right Grant
- 1997-10-14 AT AT97910793T patent/ATE233573T1/de not_active IP Right Cessation
- 1997-10-14 US US08/949,758 patent/US6083477A/en not_active Expired - Lifetime
- 1997-10-14 EP EP97910793A patent/EP0932417B1/en not_active Expired - Lifetime
- 1997-10-14 DK DK97910793T patent/DK0932417T3/da active
-
2000
- 2000-06-23 US US09/599,550 patent/US6399068B1/en not_active Expired - Lifetime
-
2002
- 2002-04-08 US US10/117,342 patent/US7033572B2/en not_active Expired - Fee Related
-
2005
- 2005-02-14 US US11/056,187 patent/US20050175582A1/en not_active Abandoned
- 2005-10-05 JP JP2005292358A patent/JP4056543B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050175582A1 (en) | 2005-08-11 |
US6399068B1 (en) | 2002-06-04 |
EP0932417B1 (en) | 2003-03-05 |
AU729515B2 (en) | 2001-02-01 |
US6083477A (en) | 2000-07-04 |
US20030031669A1 (en) | 2003-02-13 |
DE69719529D1 (de) | 2003-04-10 |
ATE233573T1 (de) | 2003-03-15 |
DE69719529T2 (de) | 2003-12-11 |
WO1998016254A1 (en) | 1998-04-23 |
JP2001503253A (ja) | 2001-03-13 |
DK0932417T3 (da) | 2003-04-14 |
AU4807997A (en) | 1998-05-11 |
ES2191827T3 (es) | 2003-09-16 |
EP0932417A1 (en) | 1999-08-04 |
JP4056543B2 (ja) | 2008-03-05 |
CA2269060A1 (en) | 1998-04-23 |
PT932417E (pt) | 2003-07-31 |
US7033572B2 (en) | 2006-04-25 |
CA2269060C (en) | 2009-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4056543B2 (ja) | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク | |
Nicholson et al. | Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma | |
US5922847A (en) | Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor | |
JP4175489B2 (ja) | 改変型超抗原と標的探索化合物との結合体及び該結合体の使用 | |
WO1996036360A1 (en) | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies | |
US6703488B1 (en) | Antibody/receptor targeting moiety for enhanced delivery of armed ligand | |
US6737064B2 (en) | Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2 | |
EP1045861B1 (en) | Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit | |
JP2004507205A (ja) | Ca19−9抗原陽性細胞の検出および除去のためのポリペプチド | |
CN117964777A (zh) | 一种接近天然分子的多肽融合分子 | |
US20030180799A1 (en) | Antibodies against plasma cells | |
WO2023125975A1 (zh) | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 | |
EP0931836A1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
JPH10508202A (ja) | 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060613 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071211 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101221 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101221 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111221 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111221 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121221 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121221 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131221 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |